In the present study, the relatively low rates of pathological complete response reflect the preponderance of oestrogen receptor-positive HER2-negative breast cancers and, as expected, higher response rates were observed in the basal-type and HER2-positive cancers. The gene discussed is ERBB2; the disease is breast cancer.